Bioregulators & Organ Support
Route(s)
Subcutaneous
Typical dose
1mg
Dosing window
Bedtime (fasted)
Receptor / target
Immune System
Properties
Not listed
Pre-mixed
No
Crystagen
← Back to Library
Protocol not independently verified Immunity Bioregulator
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Compound Profile
Crystagen is reviewed here for organ-support and bioregulator research.
Research Summary
Evidence Strength
Limited
Primary Evidence
Published literature searches and source-listed protocols
Research Focus
Organ-support research, Tissue signaling
Mechanism
Target context: Immune System
Long-Term Data
Limited or not established.
Current Consensus
Treat protocols as educational examples unless stronger sources are listed.
Route(s)
Subcutaneous
Typical dose
1mg
Dosing window
Bedtime (fasted)
Receptor / target
Immune System
Properties
Not listed
Pre-mixed
No
Protocols
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 1mg 1x Daily at bedtime fasted | Standard Khavinson protocol. Repeat 3-4 times per year. |
Protocol example for research-context comparison; verify against the evidence status and listed medical sources.
Alternative Titration 1: Extended Protocol (Goal: sustained peripheral immune cell gene program normalization with minimized peak immune activation; preferred for sensitive subjects or first cycle)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-30 | 500mcg 1x Daily at bedtime fasted | Half-dose extended cycle. For subjects sensitive to immune activation symptoms (flu-like initiation response). Lower peak NK/T-cell activation with equivalent cumulative exposure. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 2: NK Cell Cancer Surveillance Protocol (Goal: maximize NK cell cytotoxic gene program restoration for subjects with elevated cancer risk, family history, or post-cancer surveillance; combine with Vilon for upstream thymic coverage)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-5 | 500mcg 1x Daily at bedtime fasted | Entry dose. Baseline CBC with lymphocyte differential before initiating. |
| Days 6-20 | 1mg 1x Daily at bedtime fasted | Full standard dose. Run concurrent with Vilon for thymic + peripheral immune combined protocol. |
| Days 21-30 | 500mcg 1x Daily at bedtime fasted | Taper phase. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 3: Pre/Post-Infection Immune Reinforcement Protocol (Goal: rapid NK cell and T-cell gene program activation before known infectious exposure (travel, procedure) or to accelerate immune recovery post-infection)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 (1-2 weeks before known exposure) | 1mg 1x Daily at bedtime fasted | Pre-exposure NK and T-cell priming. Particularly valuable before immunologically stressful events (international travel, elective surgery, vaccination). |
| Days 1-10 (immediately post-infection/post-acute phase) | 1mg 1x Daily at bedtime fasted | Post-infection recovery course. Normalize NK and T-cell gene programs depleted by acute infectious response. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 4: Vilon + Crystagen Complete Immune Rejuvenation Stack (Goal: full hierarchical immunosenescence reversal: thymic T-cell output (Vilon) + peripheral immune effector normalization (Crystagen); most complete anti-immunosenescence protocol in the database)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-10 | Vilon 10mg 1x Daily (anytime) + Crystagen 1mg 1x Daily (bedtime fasted) | Run both standard courses concurrently. Most complete immune bioregulator protocol in the database. |
| Days 11-20 | Crystagen 1mg 1x Daily (bedtime fasted): Vilon taper optional | Extended Crystagen cycle after Vilon standard course completes. |
Alternative research-context example; not an approved-label regimen unless marked above.
Alternative Titration 5: High-Frequency Quarterly Immune Maintenance Protocol (Goal: 4 cycles per year for subjects with significant immunosenescence, post-chemotherapy immune reconstruction, or chronic infection burden)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 (Q1) | 1mg 1x Daily at bedtime fasted | Cycle 1 (January). |
| Days 1-20 (Q2) | 1mg 1x Daily at bedtime fasted | Cycle 2 (April). |
| Days 1-20 (Q3) | 1mg 1x Daily at bedtime fasted | Cycle 3 (July). |
| Days 1-20 (Q4) | 1mg 1x Daily at bedtime fasted | Cycle 4 (October). Full annual peripheral immune coverage. |
Alternative research-context example; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older, regional, or weakly indexed evidence. Entry context: target (Immune System); route Subcutaneous; timing Bedtime (fasted). Unapproved or unverified dosing examples are hypotheses, not recommendations.
Medical literature and study context
Medical-source summary: This section ties the page to medical literature, drug labels, trial registries, and regulatory sources. It is educational context only and should not be read as medical advice or a use recommendation.
| Evidence position | No approved FDA label was identified for this entry; evidence should be treated as literature context rather than validated dosing guidance. |
|---|---|
| Where studied | Studied in organ-specific peptide-bioregulator literature, often with older regional clinical reports plus preclinical or mechanistic studies. |
| Source systems checked | FDA regulatory pages; PubMed/PMC literature; ClinicalTrials.gov records |
| Target and route context | Target/receptor: Immune System. Route(s): Subcutaneous. Dosing window on page: Bedtime (fasted). |
| Protocol anchor | No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only. |
| Main evidence limit | Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard. |
Source-linked findings
- Bioregulator entries commonly rely on organ-specific peptide literature with variable indexing and older clinical traditions.
- Treat organ-system claims cautiously unless they are supported by modern, indication-specific clinical trials or labels.
- No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Protocol and study notes
- No source-backed label or clinical-trial regimen was identified for this page; protocol examples are research-context comparisons only.
- On-page protocol examples summarized for comparison: Standard Protocol: Days 1-20, 1mg 1x Daily at bedtime fasted; Alternative Titration 1: Extended Protocol (Goal: sustained peripheral immune cell gene program normalization with minimized peak immune activation; preferred for sensitive subjects or first cycle): Days 1-30, 500mcg 1x Daily at bedtime fasted.
- Key limitation: literature may be preclinical, indirect, old, region-specific, or sparse; absence of a label means no validated dosing standard.
- Monitor organ-specific labs, autoimmune/transplant context, cancer history, and the age/quality of the cited literature.
Selected medical sources
Independent evidence
Independent safety notes: No approved-label regimen was identified for this entry. Dosing examples should be treated as unverified protocol examples.
Regulatory status: no approved label identified
Storage
No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Active autoimmune disease: the broad and intense peripheral immune activation mechanism of Crystagen is directly contraindicated in any autoimmune condition where immune activation amplifies the self-reactive immune response; this includes rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, type 1 diabetes, psoriasis, and other autoimmune conditions in active phase; this is the strictest autoimmune contraindication among the Khavinson immune bioregulators.
- Organ transplant recipients on immunosuppressive therapy: Crystagen's NK cell activation, T-cell normalization, and broad immune competence restoration directly opposes the immunosuppressive regimen required to prevent rejection; absolute contraindication.
- Concurrent biologic immunosuppressive therapy (TNF-alpha inhibitors, IL-6 inhibitors, IL-17 inhibitors, JAK inhibitors): Crystagen's immune activation mechanism conflicts with the intended immunosuppressive mechanism of these biologics.
- Active hematological malignancies involving lymphoid lineages (lymphoma, CLL, T-cell malignancies): NK cell activation, T-cell normalization, and B-cell stimulation in the context of malignant lymphoid clonal expansion requires oncological evaluation.
- Known hypersensitivity to Crystagen (Lys-Glu-Asp tripeptide) or formulation excipients.
- Active severe infection requiring antimicrobial management: Crystagen's immune activation during acute severe infection could dysregulate the already activated innate immune response.
- Pregnancy: broad immune system modulation during pregnancy, where maternal immune tolerance of the semi-allogeneic fetus is critically maintained, has not been evaluated and carries theoretical risks to the maternal-fetal immune interface.
- Pediatric subjects with normally functioning immune systems: intense immune bioregulator stimulation in subjects with fully competent immune function has no established therapeutic target and could produce immune hyperactivation.
- Immune checkpoint inhibitor therapy (pembrolizumab, nivolumab, ipilimumab) for oncological indications: concurrent NK/T-cell activation with checkpoint inhibitor-mediated T-cell unleashing could produce additive immune-related adverse events (irAE) of unpredictable severity.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.
- Mild flu-like symptoms in first cycle days: the most commonly reported adverse effect; as NK cells, T-cells, and macrophages are activated and cytokine production normalizes, a transient systemic immune activation response manifests as mild fatigue, myalgia, and low-grade temperature elevation; typically resolves within 2-4 days as the immune normalization equilibrates.
- Mild lymph node awareness or tenderness: regional lymph node activation as lymphocyte proliferation and immune cell trafficking increases; benign; typically self-limiting within the first week.
- Mild fatigue: related to the metabolic demand of immune system activation; most pronounced in the first 3-5 days of a new cycle.
- Fasting requirement compliance challenge: unlike most Khavinson compounds, Crystagen requires a fasted state at bedtime; subjects who eat late or have acid reflux conditions that worsen with fasting may find this administration requirement difficult.
- Transient worsening of subclinical autoimmune manifestations: subjects with undiagnosed autoimmune predisposition may experience a mild flare of previously subclinical autoimmune symptoms as immune surveillance and reactivity are restored; warrants discontinuation and evaluation if it occurs.
- Mild skin changes: as NK cell and T-cell surveillance improves, some subjects with chronic viral skin manifestations (subclinical herpes, HPV-related) may notice transient flares as the immune system engages these previously tolerated infections more actively.
- Mild fever on initiation (rare): a small minority reports low-grade fever (< 38.0°C) in the first 1-2 days; a sign of immune activation rather than infection; resolves spontaneously without intervention.
- No serious immune adverse events documented in the Khavinson literature at standard protocol doses: Crystagen's safety profile in the aging and immunosenescence research cohorts is clean at standard doses; the most practically significant safety dimension is the autoimmune and transplant contraindication.
Compatibility
The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.